Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Revance Therapeutics
(NQ:
RVNC
)
6.560
-0.020 (-0.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
7,943,383
Open
6.580
Bid (Size)
6.530 (16)
Ask (Size)
6.550 (3)
Prev. Close
6.580
Today's Range
6.540 - 6.590
52wk Range
2.300 - 17.59
Shares Outstanding
71,829,718
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC
August 15, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, RVNC, BALY, DRQ on Behalf of Shareholders
August 13, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
Performance
YTD
-29.54%
-29.54%
1 Month
-0.61%
-0.61%
3 Month
+116.86%
+116.86%
6 Month
+8.97%
+8.97%
1 Year
-59.28%
-59.28%
More News
Read More
Gold Gains Over 1%; Starbucks Shares Move Higher
August 12, 2024
Via
Benzinga
Why Is Revance Therapeutics (RVNC) Stock Up 86% Today?
August 12, 2024
Via
InvestorPlace
Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal
August 12, 2024
Via
Benzinga
Crude Oil Surges 2%; B. Riley Financial Shares Plunge
August 12, 2024
Via
Benzinga
Exposures
Fossil Fuels
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Revance Therapeutics, Inc. (Nasdaq – RVNC), Greenbrook TMS, Inc. (OTC – GBNHF), R1 RCM Inc. (Nasdaq - RCM), Enstar Group Limited (Nasdaq – ESGR)
August 12, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
KE Holdings, KeyCorp, Revance Therapeutics, Starbucks And Other Big Stocks Moving Higher On Monday
August 12, 2024
Via
Benzinga
RVNC Investigation: Halper Sadeh LLC Is Investigating Whether the Sale of Revance Therapeutics, Inc. Is Fair to Shareholders
August 12, 2024
From
Halper Sadeh LLC
Via
Business Wire
Dow Dips 150 Points; Monday.com Posts Upbeat Earnings
August 12, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
RVNC Stock Earnings: Revance Therapeutics Beats EPS, Misses Revenue for Q2 2024
August 08, 2024
Via
InvestorPlace
Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update
August 08, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
August 01, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
July 22, 2024
Via
The Motley Fool
Stocks to Buy: 3 Breakout Stars to Transform Your Portfolio
July 11, 2024
Via
InvestorPlace
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 14, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in Upcoming Investor Conferences
May 28, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
May 22, 2024
Via
InvestorPlace
3 Underappreciated Stocks That Could 10x in 10 Years
May 12, 2024
Via
InvestorPlace
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 10, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
May 10, 2024
Via
Benzinga
These Analysts Lower Their Forecasts On Revance Therapeutics After Q1 Results
May 10, 2024
Via
Benzinga
RVNC Stock Earnings: Revance Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
May 09, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
May 09, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.